Tiziana Life Sciences (NASDAQ:TLSA) Shares Climb 1.1% – Should You Buy?

Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report) rose 1.1% during mid-day trading on Monday. The stock traded as high as $0.6107 and last traded at $0.5762. Approximately 665,310 shares changed hands during trading, an increase of 23% from the average session volume of 541,569 shares. The stock had previously closed at $0.5699.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TLSA. Wall Street Zen raised shares of Tiziana Life Sciences from a “strong sell” rating to a “sell” rating in a report on Saturday, October 24th. Weiss Ratings upgraded Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 19th. Finally, BTIG Research reissued a “buy” rating on shares of Tiziana Life Sciences in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Tiziana Life Sciences has an average rating of “Hold”.

Read Our Latest Stock Report on Tiziana Life Sciences

Tiziana Life Sciences Price Performance

The business has a 50-day moving average of $0.91 and a 200-day moving average of $1.16.

Institutional Investors Weigh In On Tiziana Life Sciences

Several institutional investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in Tiziana Life Sciences in the third quarter worth about $1,315,000. Mid American Wealth Advisory Group Inc. purchased a new stake in Tiziana Life Sciences in the second quarter worth $414,000. Goldman Sachs Group Inc. lifted its position in shares of Tiziana Life Sciences by 28.0% during the third quarter. Goldman Sachs Group Inc. now owns 152,611 shares of the company’s stock worth $169,000 after purchasing an additional 33,373 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Tiziana Life Sciences by 177.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 50,000 shares of the company’s stock worth $56,000 after purchasing an additional 32,000 shares during the last quarter.

About Tiziana Life Sciences

(Get Free Report)

Tiziana Life Sciences is a biotechnology company developing treatments for inflammatory and neurodegenerative diseases. Its development work has focused on foralumab, a fully human monoclonal antibody that targets CD3, a protein found on T cells involved in the immune response. The company is investigating an intranasal formulation of foralumab for conditions including non-active secondary progressive multiple sclerosis and Alzheimer’s disease. These uses remain investigational, and foralumab is not an approved treatment.

Further Reading

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.